Effect of metformin on outcome in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction

por Posma, RA, Lipsic, E, van der Harst, P, van der Horst, I
Publicado 2015

Development and first results of a dedicated chronic total occlusion programme

por van der Werf, H. W., Vlaar, P. J., van der Harst, P., Lipšic, E.
Publicado 2019

The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative

por van der Ende, M. Yldau, Waardenburg, Ingmar E., Lipsic, E., Bos, Jens H.J., Hak, Eelko, Snieder, H., Harst, Pim van der
Publicado 2020

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

por Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, V., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., Berg, J. M. ten, van ‘t Hof, A. W. J., Hermanides, R. S.
Publicado 2021

COVID-19-mediated patient delay caused increased total ischaemic time in ST-segment elevation myocardial infarction

por Sturkenboom, H. N., van Hattem, V. A. E., Nieuwland, W., Paris, F. M. A., Magro, M., Anthonio, R. L., Algin, A., Lipsic, E., Bruwiere, E., Van den Branden, B. J. L., Polad, J., Tonino, P., Tio, R. A.
Publicado 2022

The position of renal denervation in treatment of hypertension: an expert consensus statement

por Zeijen, V. J. M., Kroon, A. A., van den Born, B. H., Blankestijn, P. J., Meijvis, S. C. A., Nap, A., Lipsic, E., Elvan, A., Versmissen, J., van Geuns, R. J., Voskuil, M., Tonino, P. A. L., Spiering, W., Deinum, J., Daemen, J.
Publicado 2022